RFK Jr. wanted ‘gold standard’ science. mRNA just delivered it

In less than three weeks, American medicine produced two milestones worth noticing. On Aug. 5, the Food and Drug Administration approved MFLUSIVA, Moderna’s influenza vaccine for adults 50 and older — the first flu vaccine in the United States built with messenger RNA, or mRNA. Two weeks later, Moderna and Merck announced positive Phase 3…